LINC01001 and non-small cell lung carcinoma: Our results furtherly indicated that LINC01001 overexpression accelerates crizotinib-resistant NSCLC cell proliferation, inhibits apoptosis, and accelerates tumor growth via IGF2BP2/MYC axis, indicating LINC01001 regulates crizotinib-resistance NSCLC progression by modulating IGF2BP2/MYC axis.